Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free CALC Stock Alerts

CalciMedica (CALC) Competitors

CalciMedica logo
$1.60 -0.05 (-3.03%)
Closing price 10/2/2026 03:56 PM Eastern
Extended Trading
$1.71 +0.11 (+6.81%)
As of 10/2/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CALC vs. FLNA, AGFY, IXHL, SCLX, and ADXS

Should you buy CalciMedica stock or one of its competitors? CalciMedica's main competitors and comparable companies include Cassava Sciences (FLNA), Agrify (AGFY), Incannex Healthcare (IXHL), Scilex (SCLX), and Ayala Pharmaceuticals (ADXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CalciMedica compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

CalciMedica's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -58.78% -36.74%
CalciMedica N/A N/A -155.24%

Cassava Sciences currently has a consensus target price of $5.00, suggesting a potential upside of 437.11%. CalciMedica has a consensus target price of $50.00, suggesting a potential upside of 3,025.00%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Cassava Sciences has a beta of -0.65, suggesting that its stock price is 165% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

In the previous week, Cassava Sciences had 8 more articles in the media than CalciMedica. MarketBeat recorded 8 mentions for Cassava Sciences and 0 mentions for CalciMedica. Cassava Sciences' average media sentiment score of 1.23 beat CalciMedica's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Cassava Sciences Positive
CalciMedica Neutral

38.1% of Cassava Sciences shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 28.3% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cassava Sciences is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$0.87N/A
CalciMedicaN/AN/A-$29.56M-$6.80N/A

Summary

CalciMedica beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Agrify?

Agrify (NASDAQ:AGFY) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

6.0% of Agrify shares are owned by institutional investors. 2.2% of Agrify shares are owned by company insiders. Comparatively, 28.3% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Agrify has a beta of 9.96, meaning that its stock price is 896% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

CalciMedica has lower revenue, but higher earnings than Agrify. Agrify is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agrify$12.26M3.20-$41.75M-$22.65N/A
CalciMedicaN/AN/A-$29.56M-$6.80N/A

CalciMedica has a consensus price target of $50.00, indicating a potential upside of 3,025.00%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than Agrify.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agrify
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

CalciMedica has a net margin of 0.00% compared to Agrify's net margin of -424.11%. CalciMedica's return on equity of 0.00% beat Agrify's return on equity.

Company Net Margins Return on Equity Return on Assets
Agrify-424.11% -185.90% -72.67%
CalciMedica N/A N/A -155.24%

In the previous week, Agrify's average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company Overall Sentiment
Agrify Neutral
CalciMedica Neutral

Summary

CalciMedica beats Agrify on 9 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Incannex Healthcare?

CalciMedica (NASDAQ:CALC) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Incannex Healthcare had 3 more articles in the media than CalciMedica. MarketBeat recorded 3 mentions for Incannex Healthcare and 0 mentions for CalciMedica. Incannex Healthcare's average media sentiment score of 0.08 beat CalciMedica's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company Overall Sentiment
CalciMedica Neutral
Incannex Healthcare Neutral

Incannex Healthcare has higher revenue and earnings than CalciMedica. Incannex Healthcare is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CalciMedicaN/AN/A-$29.56M-$6.80N/A
Incannex Healthcare$90K447.62-$19.30M-$1.69N/A

CalciMedica has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, indicating that its share price is 597% more volatile than the broader market.

0.4% of Incannex Healthcare shares are owned by institutional investors. 28.3% of CalciMedica shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CalciMedica's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
CalciMedicaN/A N/A -155.24%
Incannex Healthcare N/A -25.62%-24.46%

CalciMedica currently has a consensus price target of $50.00, indicating a potential upside of 3,025.00%. Incannex Healthcare has a consensus price target of $18.00, indicating a potential upside of 460.75%. Given CalciMedica's stronger consensus rating and higher possible upside, equities research analysts clearly believe CalciMedica is more favorable than Incannex Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Incannex Healthcare
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Incannex Healthcare beats CalciMedica on 8 of the 14 factors compared between the two stocks.

How does CalciMedica compare to Scilex?

Scilex (NASDAQ:SCLX) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

CalciMedica has a consensus target price of $50.00, indicating a potential upside of 3,025.00%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Scilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Scilex has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

69.7% of Scilex shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 28.3% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CalciMedica has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%.

Company Net Margins Return on Equity Return on Assets
Scilex-1,414.57% N/A -147.00%
CalciMedica N/A N/A -155.24%

In the previous week, Scilex had 2 more articles in the media than CalciMedica. MarketBeat recorded 2 mentions for Scilex and 0 mentions for CalciMedica. Scilex's average media sentiment score of 0.42 beat CalciMedica's score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company Overall Sentiment
Scilex Neutral
CalciMedica Neutral

CalciMedica has lower revenue, but higher earnings than Scilex. CalciMedica is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$30.25M1.14-$358.73M-$49.70N/A
CalciMedicaN/AN/A-$29.56M-$6.80N/A

Summary

Scilex and CalciMedica tied by winning 7 of the 14 factors compared between the two stocks.

How does CalciMedica compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Company Net Margins Return on Equity Return on Assets
Ayala PharmaceuticalsN/A N/A N/A
CalciMedica N/A N/A -155.24%

In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company Overall Sentiment
Ayala Pharmaceuticals Neutral
CalciMedica Neutral

Ayala Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

CalciMedica has lower revenue, but higher earnings than Ayala Pharmaceuticals. CalciMedica is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$3.24M11.05-$48.07M-$5.02N/A
CalciMedicaN/AN/A-$29.56M-$6.80N/A

CalciMedica has a consensus price target of $50.00, suggesting a potential upside of 3,025.00%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts plainly believe CalciMedica is more favorable than Ayala Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ayala Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 28.3% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ayala Pharmaceuticals beats CalciMedica on 6 of the 11 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALC vs. The Competition

Export
MetricCalciMedicaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$10.93M$12.27B$7.15B$13.28B
Dividend YieldN/A2.65%2.54%17.33%
P/E Ratio-0.24802.26276.2626.04
Price / SalesN/A940.01656.47105.14
Price / CashN/A86.6678.8752.62
Price / Book-0.7010.5210.936.31
Net Income-$29.56M$2.86B$3.51B$362.16M
7 Day Performance-8.57%-1.58%-2.00%-1.66%
1 Month Performance-26.27%-5.55%-6.19%-4.68%
1 Year Performance-90.00%-2.19%8.03%1.57%

CalciMedica Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALC
CalciMedica
3.0062 of 5 stars		$1.60
-3.0%		$50.00
+3,025.0%		-90.0%$10.93MN/AN/A15
FLNA
Cassava Sciences
2.9533 of 5 stars		$0.89
-4.2%		$5.00
+464.3%		-74.4%$42.80MN/AN/A30
AGFY
Agrify
N/A$21.23
-1.0%		N/A-54.7%$42.52M$12.26MN/A140
IXHL
Incannex Healthcare
1.259 of 5 stars		$3.24
-2.1%		$18.00
+455.6%		-77.8%$40.65MN/AN/A12
SCLX
Scilex
0.2672 of 5 stars		$4.45
+0.9%		N/A-74.3%$37.79M$31.61MN/A34

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners
Larry's Three-Step Strategy Revealed at The Dollar Trap Summit
Larry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocu...
Brownstone Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...
Stansberry Research | Sponsoredtc pixel
New Chip takes minutes, not days
George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...
Eagle Publishing | Sponsoredtc pixel